effect of bmt status on decitabine plus ipilimumab in r/r mds/aml
Published 3 years ago • 94 plays • Length 8:35Download video MP4
Download video MP3
Similar videos
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
1:23
decitabine, venetoclax, and idh inhibitor in idh-mutated aml
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
12:33
3mensio ct pre-case planning: valve-in-valve tavr in epic/biocor
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
3:18
midiagnostics' complete blood count (cbc) - blood analysis for diagnosis and monitoring
-
2:41
an overview of the latest advances in hematology
-
2:41
onvansertib and decitabine in relapsed/refractory aml
-
2:36
outcomes of tp53-mutant aml with venetoclax and decitabine
-
1:27
quizartinib, venetoclax, and decitabine in patients with flt3-itd aml: a phase i/ii trial
-
2:16
rationale for 10-day decitabine with venetoclax for high-risk aml
-
3:21
admiral analysis: survival by mutation status in gilteritinib-treated flt3 r/r aml
-
1:38
lba: komet-001 - ziftomenib monotherapy in r/r npm1-mutated aml
-
0:36
versiti diagnostic labs | hematology
-
11:47
an ehr-compatible model to predict diabetes treatment effects
-
1:38
the search for better post-mpn aml treatment: decitabine and ruxolitinib
-
1:40
updates on the use of molecular monitoring to detect mrd in aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:14
highlights in quality management from ebmt